Daniel Tasse

Currently holds positions in DBV Technologies SA and Regenxbio Inc

Position	Company	Period
Chief Executive Officer, Director	DBV Technologies SA	March 5, 2019 -
Independent Director	Regenxbio Inc	Aug. 15, 2016 -
Director	Bellerophon Therapeutics Inc	Feb. 1, 2014 - May 14, 2019
Chief Executive Officer	DBV Technologies SA	Nov. 16, 2018 - March 5, 2019

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2024-03-12	2024-03-08	DBV Technologies SA (DBV)	B Purchase	754 53.59 €4,227,179	754	53.59	€4,227,179
2024-03-11	2024-03-08	DBV Technologies SA (DBV)	B Purchase	39,410 -6.2% 119.88 US$4,138,992	39,410 -6.2%	119.88	US$4,138,992
2015-02-23	2015-02-19	Bellerophon Therapeutics Inc (BLPH)	B Purchase	53,894 -11.2% 451.35 US$1,081,203	53,894 -11.2%	451.35	US$1,081,203